Últimas noticias sobre Jaguar Health (NASDAQ:JAGX) Bolsa

Jaguar Health

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Jaguar Health Inc

Productive and collaborative discussion on proposed pathway by the company to bring crofelemer to approval for cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies
The currently estimated US metastatic breast cancer population would qualify as an orphan population, which aligns with company's core focus on orphan diseases
Company plans to promptly pursue authorization to initiate expanded access program for patients with breast cancer who may not be eligible for a potential pivotal treatment trial with crofelemer in patients with metastatic breast cancer
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 9, 2025 / <a href="https://pr.report/ba6y">Jaguar Health, Inc.</a><a href="https://pr.report/ba7e">(NASDAQ:</a><a href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) family company Napo Pharmaceuticals (Napo) today provided a recap on the company's assessment of the in-person Type C Meeting on May 28, 2025 with the Division of Gastroenterology of the U.S. Food and Drug Administration (FDA) to discuss the statistically significant responder analysis results for adult patients with breast cancer in Napo's recently conducted Phase 3 <a href="https://pr.report/ba6z">OnTarget</a> trial.

Biotech

News

General

JAGX

Jaguar Health's Napo Pharma Advances Crofelemer For Cancer Therapy-Related Diarrhea Following FDA Type C Meeting

<h3>Gainers</h3>
<ul>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) shares increased by 72.6% to $0.47 during Wednesday's regular session. The company's market cap stands at $68.5 million. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) shares rose 26.8% to $19.3. The company's market cap stands at $116.2 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock rose 25.16% to $0.39. The company's market cap stands at $2.9 million. </li>
<li>Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) stock rose 24.53% to $1.32. The company's market cap stands at $65.8 million. </li>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) stock moved upwards by 23.0% to $6.55. The company's market cap stands at $7.2 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) stock moved upwards by 20.6% to $2.61. The company's market cap stands at $6.6 million. As per the news, the Q1 earnings report came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) shares decreased by 41.4% to $0.07 during Wednesday's regular session. The company's, Q1 earnings came out 4 days ago. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares decreased by 22.09% to $4.55. The company's market cap stands at $3.0 million. As per the press release, Q1 earnings came out 4 days ago. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares fell 18.56% to $0.01. The company's, Q1 earnings came out yesterday. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock decreased by 16.05% to $0.18. The market value of their outstanding shares is at $5.2 million. As per the press release, Q1 earnings came out 4 days ago. </li>
<li>ABVC BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVC#NASDAQ">ABVC</a>) stock declined by 13.87% to $1.18. The market value of their outstanding shares is at $19.7 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares decreased by 12.58% to $1.46. The company's market cap stands at $4.1 million. The company's, Q1 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ABVC

AKYA

APLM

APVO

BDSX

EYEN

GTBP

HCTI

KDLY

KLTO

PTPI

12 Health Care Stocks Moving In Wednesday's Intraday Session

WIIM

Jaguar Health shares are trading lower after the company announced the pricing of a $1.5 million registered direct offering of 246,306 shares at $6.09 per share.

<a href="https://pr.report/amzv">Jaguar Health, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) ("Jaguar" or "the Company"), today announced that it has entered into definitive agreements for the purchase and sale of 246,306 shares of common stock at a purchase price of $6.09 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company agreed to issue to investors unregistered warrants to purchase up to 492,612 shares of common stock at an exercise price of $5.84 per share that will be immediately exercisable upon issuance and will expire on the earlier of (i) 24 months from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event. The closing of the offering is expected to occur on or about May 22, 2025, subject to the satisfaction of customary closing conditions.
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.
The gross proceeds to the Company from the offering are expected to be approximately $1.5 million before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for general corporate purposes, including growth capital, working capital, operating expenses, repayment of outstanding convertible promissory notes that are not converted into Common Stock by holders, and capital expenditures.

Offerings

Jaguar Health Prices $1.5M Registered Direct Offering Of 246,306 Shares At A Price Of $6.09/Share

As <a href="https://jaguarhealth.gcs-web.com/news-releases/news-release-details/proof-concept-results-show-crofelemer-reduced-total-parenteral">announced</a>, initial proof-of-concept (POC) results from distinct ongoing investigator-initiated trial (IIT) in Abu Dhabi show crofelemer reduced total parenteral support in a pediatric MVID patient with intestinal failure by up to 27%; per the IIT protocol, patient was taken off crofelemer after 12 weeks of treatment for a period of 30 days, but was restarted on daily crofelemer treatment after just 8 days, as patient's symptoms were worsening
Additional POC IIT results expected throughout 2025 for MVID; results from company's MVID Phase 2 study expected with completion of treatment in H2 2026
Ground-breaking results in single-digit number of MVID patients could potentially lead to expedited approval in the EU through <a href="https://www.ema.europa.eu/en/human-regulatory-overview/research-development/prime-priority-medicines">PRIME</a> and to <a href="https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy">Breakthrough Therapy</a> designation in the US
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / May 20, 2025 / <a href="https://pr.report/als3">Jaguar Health, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) family companies <a href="https://pr.report/als5">Napo Pharmaceuticals, Inc.</a> (Napo) and <a href="https://pr.report/als6">Napo Therapeutics S.p.A.</a> today announced that the first patient has been randomized in Napo's randomized, double-blind, placebo-controlled Phase 2 clinical trial to evaluate the safety and efficacy of the novel crofelemer oral powder for solution formulation in pediatric patients with intestinal failure due to the ultrarare disease MVID.
Patients with MVID suffer from devastating diarrhea and dehydration caused by this debilitating, lifelong condition. These pediatric patients often require lifelong and life-sustaining total parenteral nutrition (TPN) with additional supplemental intravenous (IV) fluids, termed total parenteral support, which is the standard of care for MVID, for up to 7 days a week greater than 50% of the time each day to provide adequate nutrient and electrolyte support. While crucial for MVID patients, TPN carries a significant risk of morbidity and mortality due to infections, metabolic complications, liver and/or kidney disease, and a risk of neurodevelopmental delay. There are currently no approved drug treatments for MVID.
Based on the initial proof-of-concept findings presented last month at the 11th Annual ELITE PED-GI Congress, crofelemer's novel antisecretory mechanism of action appears to have the potential to provide a novel therapeutic option to modify the disease progression associated with intestinal failure due to MVID in pediatric patients, as evidenced by the reductions in total parenteral support and potential to improve the quality of life of MVID patients.

Jaguar Health Says First Patient Randomized In Napo's Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial To Evaluate Safety And Efficacy Of Crofelemer In Pediatric Patients With MVID

First Berlin analyst Christian Orquera initiates coverage on Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) with a Buy rating and announces Price Target of $60.

Price Target

Initiation

Analyst Ratings

First Berlin Initiates Coverage On Jaguar Health with Buy Rating, Announces Price Target of $60

<h3>Gainers</h3>
<ul>
<li>Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) stock rose 18.2% to $2.14 during Thursday's after-market session. The company's market cap stands at $104.5 million. </li>
<li>Meihua Intl Medical Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) stock increased by 13.8% to $0.41. The market value of their outstanding shares is at $10.4 million. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) stock increased by 13.34% to $6.2. The company's market cap stands at $4.1 million. The company's, Q1 earnings came out today. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock rose 12.02% to $6.15. The market value of their outstanding shares is at $333.8 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock increased by 9.36% to $1.81. The company's market cap stands at $2.6 million. </li>
<li>Sensus Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRTS#NASDAQ">SRTS</a>) stock rose 9.22% to $5.09. The company's market cap stands at $83.4 million. The company's, Q1 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares fell 69.4% to $0.01 during Thursday's after-market session. </li>
<li>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) shares decreased by 24.74% to $43.99. The company's market cap stands at $8.2 billion. As per the press release, Q4 earnings came out today. </li>
<li>Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) stock fell 24.32% to $16.0. The market value of their outstanding shares is at $1.4 billion. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) shares declined by 10.98% to $0.24. The company's market cap stands at $12.3 million. </li>
<li>Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) shares declined by 8.99% to $2.33. The market value of their outstanding shares is at $477.7 million. As per the news, the Q1 earnings report came out today. </li>
<li>Q32 Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTTB#NASDAQ">QTTB</a>) stock declined by 8.05% to $1.6. The market value of their outstanding shares is at $19.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CABA

DOCS

MHUA

QTTB

SRTS

TSHA

TVTX

12 Health Care Stocks Moving In Thursday's After-Market Session

Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) reported quarterly losses of $(16.70) per share which beat the analyst consensus estimate of $(18.00) by 7.22 percent. This is a 80.83 percent increase over losses of $(87.12) per share from the same period last year. The company reported quarterly sales of $2.21 million which missed the analyst consensus estimate of $2.82 million by 21.52 percent. This is a 5.83 percent decrease over sales of $2.35 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Jaguar Health Q1 EPS $(16.70) Beats $(18.00) Estimate, Sales $2.21M Miss $2.82M Estimate

ACOG

AENT

AIRI

AMAT

AREN

BABA

BCLI

BEKE

BFRI

BHST

BIRK

BLIN

BNZI

BRAG

BTBT

BTDR

CAVA

CSIQ

CYCC

DFLI

DTIL

DTST

DUOT

EDAP

EDBL

FLNT

FTLF

GAMB

GAME

GLOB

GORV

GOSS

GSX Techedu Inc. American Depositary Shares

GOTU

HAFN

IMCC

INKT

IVVD

KORE

KPLT

KULR

LFWD

LGCY

LMFA

LPTH

LTRN

MITQ

MRSN

NICE

NRXP

NTES

NVVE

NXPL

OMER

ONDS

ORGN

PAVM

PHGE

PIII

PLBY

POCI

PPSI

PVLA

QUBT

RIME

RNXT

ROLR

SANW

SCWO

SIDU

SNYR

SOBO

SPCE

SRXH

SWKH

TIVC

TLSI

TRAK

TSSI

Earnings Scheduled For May 15, 2025

631,922 Shares of Common Stock Issuable Upon the Conversion of Outstanding Notes
622,584 Shares of Common Stock Issuable Upon the Exercise of Outstanding Common Warrants
37,376 Shares of Common Stock Issuable Upon the Exercise of Outstanding Placement Agent Warrants
This prospectus relates to the resale of up to 1,291,882 shares of Jaguar Health, Inc. (the "Company," "we," "our" or "us") voting common stock, par value $0.0001 per share (the "Common Stock"), by the Selling Stockholders listed in this prospectus (the "Selling Stockholders"). The shares of Common Stock registered for resale pursuant to this prospectus consist of (i)&nbsp;631,922 shares of Common Stock (the "Conversion Shares") issuable upon the conversion of the 6% convertible promissory notes (the "Notes"), (ii)&nbsp;622,584 shares of Common Stock (the "Common Warrant Shares") issuable upon the exercise of common warrants (the "Common Warrants"), and (iii)&nbsp;37,376 shares of Common Stock (the "Placement Agent Warrant Shares," and together with the Common Warrant Shares, the "Warrant Shares") issuable upon the exercise of certain warrants issued to our placement agent (the "Placement Agent Warrants" and together with the Common Warrants, the "Warrants"). The Notes and Warrants were issued to the Selling Stockholders in a private placement offering (the "Private Placement") that closed on March&nbsp;31, 2025.
For additional information about the Private Placement, see "Private Placement."
The Notes are immediately convertible, at each holder's option, in part or in full, into Conversion Shares at a conversion price of $5.535 per share for holders who are not an officer, director, employee or consultant of the Company (collectively, a "Company Insider"), and $5.555 per share for holders who are Company Insiders. The Common Warrants have an exercise price of $5.41 per share for holders who are not Company Insiders, and $5.43 per share for holders who are Company Insiders, and are exercisable immediately upon issuance and will expire on the earlier of (i)&nbsp;five years from the date of issuance, (ii)&nbsp;the consummation of a fundamental transaction and (iii)&nbsp;the consummation of a liquidation event. The Placement Agent Warrants have substantially the same terms as the Warrants, except that the Placement Agent Warrants have an exercise price of $6.9188 per share.

Jaguar Health Registers 1.29M Shares Of Common Stock For Resale From Private Placement That Closed On March 31, 2025, Including Shares Issuable From Convertible Notes, Common Warrants, And Placement Agent Warrants

<h3>Gainers</h3>
<ul>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares increased by 45.1% to $4.15 during Wednesday's after-market session. The company's market cap stands at $3.4 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares increased by 15.64% to $0.2. The company's market cap stands at $5.1 million. </li>
<li>Ainos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIMD#NASDAQ">AIMD</a>) stock rose 13.18% to $0.6. The market value of their outstanding shares is at $9.2 million. </li>
<li>Processa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) stock increased by 13.16% to $0.28. The company's market cap stands at $1.4 million. </li>
<li>Auna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AUNA#NYSE">AUNA</a>) shares rose 11.43% to $7.7. The market value of their outstanding shares is at $569.8 million. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) shares rose 10.08% to $1.31. The market value of their outstanding shares is at $21.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>INVO Fertility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVF#NASDAQ">IVF</a>) shares declined by 7.5% to $2.21 during Wednesday's after-market session. The company's market cap stands at $10.9 million. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) shares fell 7.31% to $0.19. The market value of their outstanding shares is at $4.8 million. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) stock declined by 6.95% to $11.39. The market value of their outstanding shares is at $7.6 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) shares declined by 6.94% to $0.31. The market value of their outstanding shares is at $19.2 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares fell 6.46% to $0.29. The company's market cap stands at $11.5 million. </li>
<li>Baird Medical Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) stock fell 6.26% to $5.55. The market value of their outstanding shares is at $201.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIMD

AUNA

BDMD

GCTK

IRIX

NAOV

PASG

PCSA

PLRZ

12 Health Care Stocks Moving In Wednesday's After-Market Session

Jaguar to host investor webcast today at 8:30 AM Eastern to review the initial results from the proof-of-concept study of crofelemer for MVID and SBS-IF presented April 26 at the <a href="https://pr.report/9xgt">Annual ELITE PED-GI Congress</a>; Click <a href="https://pr.report/9xgu">here</a> to register
There are no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management including total parenteral nutrition (TPN) - which carries the risk of morbidity, infections, metabolic complications, liver and kidney problems, and neurodevelopmental delay
This proof-of-concept data in MVID supports crofelemer's potential inclusion in the European Medicines Agency's (EMA) <a href="https://pr.report/9xgv">PRIME</a> program for expediated and assisted regulatory approval in the EU as well as FDA's <a href="https://pr.report/9xgw">Breakthrough Therapies</a> program for expedited regulatory approval in the US
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / April 30, 2025 / <a href="https://pr.report/9xgb">Jaguar Health, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) family companies <a href="https://pr.report/9xgd">Napo Pharmaceuticals</a> (Napo) and <a href="https://pr.report/9xge">Napo Therapeutics</a> today announced initial proof-of-concept results showing that a novel liquid formulation of crofelemer reduced the required TPN and/or supplementary intravenous fluids, collectively referred to as parenteral support (PS) in patients with intestinal failure due to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) by up to 27% and 12.5% respectively. In addition, this data showed that crofelemer reduced stool volume output and/or frequency of watery stools, and increased urine output - an indicator of improved nutrient oral absorption.

Jaguar Health Announces Initial Proof-Of-Concept Results Showing That Novel Liquid Formulation Of Crofelemer Reduced Required TPN And/Or Supplementary Intravenous Fluids In MVID And SBS-IF Patients

The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for crofelemer for MVID; Click <a href="https://viavid.webcasts.com/starthere.jsp?ei=1718118&amp;tp_key=02fe2f82c4">here</a> to register
There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management
This data was presented at the <a href="https://www.elite-pedgi.com/">Annual ELITE PED-GI Congress</a> by Dr. Mohamad Miqdady, a recognized leader in pediatric gastroenterology and the primary investigator for this study

Events

Jaguar Health To Present Initial Results From Proof-of-Concept Study of Crofelemer For Rare Diseases Microvillus Inclusion Disease And Short Bowel Syndrome With Intestinal Failure

<h3>Gainers</h3>
<ul>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) stock increased by 61.0% to $12.98 during Friday's regular session. The company's market cap stands at $8.7 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares increased by 42.96% to $2.26. The company's market cap stands at $31.0 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares rose 23.66% to $0.28. The market value of their outstanding shares is at $3.9 million. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) stock rose 15.48% to $7.68. The market value of their outstanding shares is at $45.5 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) stock rose 15.06% to $3.97. The company's market cap stands at $2.1 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock rose 14.45% to $0.53. The market value of their outstanding shares is at $2.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Coeptis Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) shares declined by 36.9% to $7.86 during Friday's regular session. The company's market cap stands at $25.4 million. </li>
<li>Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) stock fell 36.76% to $23.21. The company's market cap stands at $17.1 billion. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares fell 33.66% to $0.6. The company's market cap stands at $9.0 million. </li>
<li>VYNE Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) stock declined by 23.75% to $1.43. The company's market cap stands at $21.1 million. </li>
<li>Sutro Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>) stock decreased by 21.4% to $1.02. The company's market cap stands at $85.6 million. </li>
<li>Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) stock declined by 21.1% to $15.47. The market value of their outstanding shares is at $101.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COEP

INTS

NDRA

RBOT

SMMT

STRO

SXTC

VYNE

12 Health Care Stocks Moving In Friday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) stock moved upwards by 37.6% to $1.1 during Thursday's regular session. The company's market cap stands at $5.9 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares increased by 26.43% to $0.4. The market value of their outstanding shares is at $9.2 million. </li>
<li>Zhengye Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) shares increased by 24.8% to $9.76. The market value of their outstanding shares is at $462.5 million. </li>
<li>Community Health Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) shares increased by 24.69% to $3.03. The market value of their outstanding shares is at $420.9 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares increased by 23.43% to $0.79. The market value of their outstanding shares is at $19.1 million. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares moved upwards by 19.94% to $8.0. The market value of their outstanding shares is at $5.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares decreased by 26.3% to $0.66 during Thursday's regular session. The company's market cap stands at $3.9 million. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares decreased by 23.85% to $0.99. The company's market cap stands at $15.0 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares declined by 16.08% to $3.08. The company's market cap stands at $5.0 million. </li>
<li>Metsera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) stock fell 15.17% to $20.0. The company's market cap stands at $2.1 billion. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock declined by 12.5% to $0.28. The market value of their outstanding shares is at $2.2 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares decreased by 11.41% to $0.87. The market value of their outstanding shares is at $5.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSGM

CERO

ENSC

MTSR

NCNA

PSTV

RNAZ

VTAK

ZYBT

12 Health Care Stocks Moving In Thursday's Intraday Session

Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and microvillus inclusion disease (MVID) and is being evaluated to serve as a potential therapeutic option to manage intestinal failure in these patients
There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management
Proof-of-concept data in MVID from this study would provide support for crofelemer's potential inclusion in the EMA's <a href="https://www.ema.europa.eu/en/human-regulatory-overview/research-development/prime-priority-medicines">PRIME</a> program for novel medicines targeting unmet medical needs and the FDA's <a href="https://www.fda.gov/regulatory-information/food-and-drug-administration-safety-and-innovation-act-fdasia/fact-sheet-breakthrough-therapies">Breakthrough Therapies</a> program
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / April 17, 2025 / <a href="https://pr.report/8vx8">Jaguar Health, Inc.</a> <a href="https://pr.report/8vx9">(NASDAQ:</a><a href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) family companies <a href="https://pr.report/8vxa">Napo Pharmaceuticals</a> (Napo) and <a href="https://pr.report/8vxb">Napo Therapeutics</a> today announced that preliminary results from the ongoing pediatric investigator-initiated trial (IIT) of a novel liquid formulation of crofelemer, Jaguar's novel plant-based anti-secretory prescription drug, for various congenital diarrheal disorders (CDD), including MVID and SBS with intestinal failure (SBS-IF), will be presented by Dr. Mohamad Miqdady at the April 24-26, 2025 <a href="https://pr.report/8vxc">Annual ELITE PED-GI Congress</a> in Abu Dhabi in the United Arab Emirates.
MVID and SBS-IF, rare orphan diseases requiring intensive parenteral nutrition and support, have severe morbidity and mortality implications and impact the quality of life of both patients and their caregivers. There are currently no approved drug treatments for MVID. A key value driver would be a reduction in total parenteral nutrition (TPN).
"Patients with MVID and SBS-IF suffer from devastating diarrhea and dehydration caused by these debilitating, lifelong conditions. These patients are frequently on TPN for as long as 20 hours a day, seven days a week - and TPN carries a significant risk of morbidity, including infections, metabolic complications, and liver problems," said Dr. Miqdady, the principal investigator for this study. "I look forward to presenting preliminary, proof-of-concept results from this study at the ELITE PED-GI Congress."
This ongoing proof-of-concept study is evaluating crofelemer's potential to be safely administered to patients with MVID, SBS-IF, and other CDDs in escalating doses, improve stool formation, improve the absorption of nutrients, and lower TPN needs - which have never been achieved in an MVID patient. The study also provides the opportunity to evaluate whether any potential benefit provided by crofelemer in participating patients ceases after treatment with crofelemer is discontinued.

Jaguar Health Announces Preliminary Results From Ongoing Pediatric Investigator-Initiated Trial Of A Novel Liquid Formulation Of Crofelemer Will Be Presented By Dr. Mohamad Miqdady At April 24-26, 2025 Annual ELITE PED-GI Congress in Abu Dhabi in the United Arab Emirates

The statistically significant responder analysis results for Mytesi&#xAE; (crofelemer) in the Phase 3 <a href="https://clinicaltrials.gov/study/NCT04538625">OnTarget</a> study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster presentation at the <a href="https://sabcs.org/Symposium-Overview-2024">San Antonio Breast Cancer Symposium</a>
Late-breaker abstract accepted by <a href="https://mascc.org/annualmeeting2025/">MASCC</a> shows additional significant results for breast cancer subgroup
Jaguar planning to meet with FDA in Q2 2025 to discuss possible pathways for crofelemer approval for prophylaxis of diarrhea in patients with breast cancer
A second late-breaker abstract, related to the results of a screening survey of cancer patients about oral mucositis and a follow-up focus group, has also been accepted for presentation at MASCC's 2025 Annual Meeting
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / April 15, 2025 / <a href="https://pr.report/9ein">Jaguar Health, Inc.</a> <a href="https://pr.report/9eio">(NASDAQ:</a><a href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) ("Jaguar" or the "Company") family company Napo Pharmaceuticals ("Napo") today announced that the late-breaker abstract Napo submitted to MASCC on additional significant results in adult breast cancer patients from the OnTarget study has been accepted for presentation as an oral rapid e-poster at MASCC's June 26-28, <a href="https://pr.report/9eip">2025 Annual Meeting</a> in Seattle, Washington. The authors include Pravin Chaturvedi, PhD, who is Jaguar's Chief Scientific Officer and Chair of Napo's Scientific Advisory Board, as well as leading oncologists and cancer patient advocates.
The abstract is titled OnTarget: Crofelemer or Placebo for the Prophylaxis of Diarrhea in Adults with Solid Tumors Initiating Targeted Therapy ± Chemotherapy (Tt/C)
"We're very pleased about the acceptance by MASCC of this new abstract, which describes the proportion of breast cancer patients who were continuous responders for the entire 3-month period of the OnTarget trial compared to breast cancer patients in the placebo arm of the study," said Lisa Conte, Jaguar's president and CEO.
"As a cancer patient, having options to manage the side effects of life saving drugs is very important. I believe the published results of crofelemer for the prophylaxis of cancer therapy-related are very exciting and compelling," said Dr. Kelly Shanahan, a former clinician and a metastatic breast cancer patient who serves on Napo's Scientific Advisory Board (SAB).
As announced, the U.S. Food and Drug Administration (FDA) has granted Napo a Type C Meeting in the second quarter of 2025 to discuss the responder analysis in the prespecified subgroup of patients with breast cancer for crofelemer in Napo's Phase 3 OnTarget trial. Patients with breast cancer accounted for 183 of the 287 participants in this unprecedented prophylactic clinical trial recently conducted by Napo for diarrhea in adults with solid tumors receiving targeted therapy with or without standard chemotherapy. The American Cancer Society expects 316,950 new cases of breast cancer diagnosed in women in the US in 2025,1 and it's estimated that there were 4 million US women with a history of invasive breast cancer in 2022.2
"Diarrhea is a common side effect of targeted cancer therapies and can lead to dose changes, treatment delays, or cessation of treatment altogether, all of which can impact patient outcomes. We are very happy to have been granted a meeting with the FDA to review the positive OnTarget results in breast cancer patients and our goal is to discuss the most efficient pathways to make crofelemer - our novel, oral plant-based prescription medicine - available to this patient population for cancer therapy-related diarrhea (CTD)," said Conte.
Members of Napo's SAB are expected to join Jaguar representatives at the FDA meeting in the second quarter of 2025.
As previously announced, the initial top line results from the OnTarget study showed that the multicenter, double-blind, placebo-controlled pivotal clinical trial did not meet its primary endpoint for the prespecified analysis of all tumor types. The subgroup analysis in adult breast cancer patients indicates that crofelemer achieved significant results in this subgroup.
Napo today also announced that a second late-breaker abstract, related to the results of a recent Napo-sponsored screening survey of cancer patients about oral mucositis and a follow-up focus group, has also been accepted for presentation at MASCC's 2025 Annual Meeting. The abstract is titled Beyond the Pain: Patient Insights on Oral Mucositis in Cancer Treatment.
"Oral mucositis is a common, painful, and life-altering side effect of cancer treatment, frequently disrupting eating, speaking, sleeping, and social interactions. Capturing real-world patient experiences and insights can help to identify patient priorities and co-create solutions to support prevention and management of oral mucositis and enhance quality of life," said Stacey Tinianov, 11-year cancer survivor and founder of <a href="https://pr.report/9eiq">Advocates for Collaborative Education</a> who serves on Napo's SAB. "I am delighted and honored that the results of the screening survey and focus group will be presented at MASCC's Annual Meeting this June."
Ms. Tinianov coordinated the screening survey and focus group in conjunction with cancer patients who serve as Ambassadors for Napo's ongoing <a href="https://pr.report/9eir">Make Cancer Less Shitty</a> (MCLS) patient advocacy program. The goal of the MCLS program is to drive awareness of cancer supportive care gaps and needs, bring together patients, advocates, researchers, and clinicians, and, most importantly, to amplify the voice of patients about the importance of supportive care.
"Oral mucositis has impacted my daily life constantly since 2016. Without proper supportive care, I have raw mouth sores and ulcerations from my gums and lips all the way down my throat. When severe, it impacts what I am able to eat, how I'm able to eat, and sometimes my ability to talk. The pain and irritation from oral mucositis affects my sleep and my self-confidence," said JJ Singleton, a metastatic colon cancer survivor and an Ambassador for Napo's MCLS patient advocacy program.
<a href="https://pr.report/9eis">MASCC</a> is an international, interdisciplinary organization dedicated to the practice, education and research of supportive care in cancer. The organization's mission is to continually improve the supportive care of people with cancer - from diagnosis through to survival or end-of-life care.

Jaguar Health Says Late-Breaker Abstract On Addl Results In Adult Breast Cancer Patients From OnTarget Study Accepted For Presentation As Oral Rapid E-poster At MASCC Annual Meeting

Jaguar Health, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) ("Jaguar" or "the Company"), announced today that Jaguar's president and chief executive officer Lisa Conte, three other members of the Company's board of directors, and seven other C-suite and senior executives of Jaguar along with selected institutional and accredited investors (each, an "Investor") entered into securities purchase agreements, pursuant to which the Company will issue up to $3.448 million aggregate principal amount of convertible promissory notes (collectively, the "Notes") to such Investors in a private placement priced at-the-market under Nasdaq rules. The Notes will have a 3-month maturity, will bear interest at 6% per annum, and will be convertible immediately at the option of the Investors into shares of the Company's common stock.

Jaguar Health Announces $3.448M Private Placement Of Convertible Promissory Notes With CEO, Board Members, And Senior Executives Participating; Notes Have A 3-Month Maturity, 6% Interest, Will Be Convertable Immediately Into Common Stock

<h3>Gainers</h3>
<ul>
<li>Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) shares increased by 49.0% to $0.13 during Tuesday's regular session. The market value of their outstanding shares is at $3.4 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock increased by 24.37% to $23.01. The company's market cap stands at $299.4 million. </li>
<li>Opus Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRD#NASDAQ">IRD</a>) shares increased by 20.0% to $1.13. The market value of their outstanding shares is at $35.6 million. </li>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) shares moved upwards by 19.85% to $2.9. The market value of their outstanding shares is at $122.6 million. </li>
<li>OSR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) stock increased by 19.12% to $1.58. The market value of their outstanding shares is at $30.5 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) stock rose 18.67% to $19.32. The market value of their outstanding shares is at $108.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Avenue Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) shares fell 47.2% to $0.45 during Tuesday's regular session. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) stock decreased by 40.6% to $0.28. The company's market cap stands at $4.5 million. </li>
<li>Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) shares declined by 27.76% to $0.92. The company's market cap stands at $71.6 million. The company's, Q4 earnings came out yesterday. </li>
<li>Gyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) stock fell 26.51% to $9.03. The company's market cap stands at $774.5 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares fell 23.2% to $0.13. The market value of their outstanding shares is at $2.3 million. </li>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares declined by 20.82% to $80.25. The company's market cap stands at $7.6 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATXI

GYRE

HURA

HYPR

OSRH

SRPT

SYRS

TNXP

VRPX

12 Health Care Stocks Moving In Tuesday's Intraday Session

Jaguar Health shares are trading lower after the company announced a 1-for-25 reverse stock split.

Press Releases

Jaguar Health Reports First Quarter 2025 Financials

Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream

First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)

Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream

Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight Series

Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Presenting on Emerging Growth Conference 83 Day 1 on June 17; Register to live stream

AEMD

ASPI

ATCH

Comments

Jaguar Health

Noticias

Últimas noticias sobre Jaguar Health (NASDAQ:JAGX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL